Triple-action diabetes jab shown to reduce blood sugar and body weight

A new weekly injection called retatrutide for type 2 diabetes has shown significant results in phase 3 trials, reducing blood sugar and body weight substantially. Patients lost over four times more weight and achieved more than twice the blood sugar reduction compared to placebo.

Type 2 diabetes affects millions globally. More effective treatments are crucial for improving patient quality of life and preventing serious complications.

Retatrutide is designed to control appetite and blood sugar but also increase body’s energy expenditure, unlike other drugs A new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo. The triple hormone drug mimics three gut hormones that help control your appetite, blood sugar and metabolism: GLP-1, GIP and glucagon. Unlike other diabetes medications such as Ozempic and Wegovy,…